

Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031

Market Report | 2023-07-11 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031

Global Neoantigen Cancer Vaccine Market Outlook:

The global neoantigen cancer vaccine market size was valued at USD 68.9 million in 2022, driven by the growing need for effective and personalized treatment across the globe. The market size is anticipated to grow at a CAGR of 69.4% during the forecast period of 2023-2031 to achieve a value of USD 8872.5 million by 2031.

Neoantigen Cancer Vaccine: Introduction

Neoantigen cancer vaccines are a novel approach to cancer immunotherapy that leverages the unique mutations found in individual tumors to stimulate the patient's immune system to specifically target and eliminate cancer cells. Neoantigens are tumor-specific antigens that arise from somatic mutations and are not present in normal tissues, making them ideal targets for personalized cancer vaccines.

The introduction of neoantigen cancer vaccines represents a significant advancement in precision medicine, as these vaccines can be tailored to each patient's specific tumor profile. By analyzing the genomic sequencing data of a patient's tumor, scientists can identify the neoantigens present and design a vaccine that specifically targets those antigens.

Key Trends in the Global Neoantigen Cancer Vaccine Market

Key Trends in neoantigen cancer vaccine development market include:

- Personalized Medicine: Neoantigen cancer vaccines exemplify the shift towards personalized medicine, as they are designed based on the unique genetic profile of each patient's tumor. This approach allows for targeted therapy and potentially improved treatment outcomes.
- Advances in Genomic Sequencing: The availability of next-generation sequencing technologies and bioinformatics tools has greatly facilitated the identification of neoantigens. The ability to rapidly and cost-effectively sequence tumor genomes has accelerated the development and application of neoantigen cancer vaccines.
- Combination Therapies: Neoantigen cancer vaccines are often used in combination with other treatment modalities, such as checkpoint inhibitors or chemotherapy. Combining these therapies can enhance the immune response and potentially improve patient outcomes.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Vaccine Delivery Systems: Researchers are exploring various vaccine delivery systems, including nanoparticles, viral vectors, and RNA-based platforms, to enhance the effectiveness of neoantigen vaccines. These delivery systems aim to optimize the immune response and increase the durability of the vaccine's effects.
- Clinical Trials and Regulatory Pathways: Neoantigen cancer vaccines are currently being evaluated in clinical trials to assess their safety and efficacy. The results of these trials will help shape the regulatory pathways for their approval and subsequent commercialization.
- Collaboration and Partnerships: The development of neoantigen cancer vaccines often involves collaborations between academic institutions, pharmaceutical companies, and biotechnology firms. These partnerships leverage expertise and resources to advance research and accelerate the translation of these vaccines into clinical practice.

Global Neoantigen Cancer Vaccine Market Segmentations

Market Breakup by Product Type

- Personalized Neoantigen Vaccine
- Off-the Shelf Neoantigen Vaccine

Market Breakup by Neoantigen Type

- Synthetic Long Peptide (SLP)
- Dendritic Cell
- Nucleic Acid
- Tumor Cell

Market Breakup by Route of Administration

- Intravenous
- Intramuscular
- Transdermal
- Others

Market Breakup by Cell

- Autologous
- Allogenic

Market Breakup by Technology

- RNA Sequencing
- Whole Genome Sequencing
- HLA Typing
- Others

Market Breakup by Delivery Mechanism

- Liposomes
- Virosomes
- Electroporation
- Gene Gun
- Others

Market Breakup by Applications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Lung, Melanoma
- Gastrointestinal
- Brain Cancer
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Neoantigen Cancer Vaccine Market Scenario

The market for neoantigen cancer vaccines is still in its early stages, but it holds immense potential for revolutionizing cancer treatment. Neoantigen cancer vaccines offer a personalized and targeted approach to fighting cancer by harnessing the power of the patient's immune system. As a result, they have garnered significant interest from researchers, pharmaceutical companies, and investors.

The market introduction of neoantigen cancer vaccines is driven by several factors. First and foremost, the rising incidence of cancer globally and the growing need for effective and personalized treatment options are propelling the demand for innovative therapies like neoantigen cancer vaccines.

Additionally, advancements in genomic sequencing technologies and bioinformatics tools have significantly accelerated the identification and characterization of neoantigens, making the development of neoantigen cancer vaccines more feasible and efficient.

Collaborations between academic institutions, pharmaceutical companies, and biotechnology firms are playing a crucial role in driving the market forward. These collaborations bring together the expertise and resources necessary to advance research, conduct clinical trials, and develop effective vaccines.

The market for neoantigen cancer vaccines is also influenced by regulatory pathways and reimbursement mechanisms. As clinical trials progress and promising results emerge, regulatory agencies are working to establish guidelines and approval processes specific to neoantigen vaccines. The successful navigation of these regulatory pathways will be crucial for market entry and commercialization.

Global Neoantigen Cancer Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- OSE Immunotherapeutics SA
- Gritstone bio, Inc.
- BioNTech SE
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Merck & Co. Inc.
- Moderna Inc.
- Avidea Technologies, Inc.
- Eli Lilly and Company
- Vaccibody AS
- Agenus Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Novogene Co., Ltd.
- ZIOPHARM Oncology Inc.
- ISA Pharmaceuticals B.V.
- BrightPath Biotherapeutics Co., Ltd.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Neoantigen Cancer Vaccine Market Overview
- 3.1 Global Neoantigen Cancer Vaccine Market Historical Value (2016-2022)
- 3.2 Global Neoantigen Cancer Vaccine Market Forecast Value (2023-2031)
- 4 Global Neoantigen Cancer Vaccine Market Dynamics
- 4.1 Market Drivers and Constraints
- 4.2 SWOT Analysis
- 4.3 Porter's Five Forces Model
- 4.4 Key Demand Indicators
- 4.5 Key Price Indicators
- 4.6 Industry Events, Initiatives, and Trends
- 4.7 Value Chain Analysis
- 5 Global Neoantigen Cancer Vaccine Market Segmentation
- 5.1 Global Neoantigen Cancer Vaccine Market by Product Type
- 5.1.1 Market Overview
- 5.1.2 Personalized Neoantigen Vaccine
- 5.1.3 Off-the Shelf Neoantigen Vaccine
- 5.2 Global Neoantigen Cancer Vaccine Market by Neoantigen Type
- 5.2.1 Market Overview
- 5.2.2 Synthetic Long Peptide (SLP)
- 5.2.3 Dendritic Cell
- 5.2.4 Nucleic Acid
- 5.2.5 Tumour Cell
- 5.3 Global Neoantigen Cancer Vaccine Market by Route of Administration
- 5.3.1 Market Overview
- 5.3.2 Intravenous
- 5.3.3 Intramuscular
- 5.3.4 Transdermal
- 5.3.5 Others
- 5.4 Global Neoantigen Cancer Vaccine Market by Cell
- 5.4.1 Market Overview
- 5.4.2 Autologous
- 5.4.3 Allogenic

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5 Global Neoantigen Cancer Vaccine Market by Technology
 - 5.5.1 Market Overview
 - 5.5.2 RNA Sequencing
 - 5.5.3 Whole Genome Sequencing
 - 5.5.4 HLA Typing
 - 5.5.5 Others
- 5.6 Global Neoantigen Cancer Vaccine Market by Delivery Mechanism
 - 5.6.1 Market Overview
 - 5.6.2 Liposomes
 - 5.6.3 Virosomes
 - 5.6.4 Electroporation
 - 5.6.5 Gene Gun
 - 5.6.6 Others
- 5.7 Global Neoantigen Cancer Vaccine Market by Applications
 - 5.7.1 Market Overview
 - 5.7.2 Lung, Melanoma
 - 5.7.3 Gastrointestinal
 - 5.7.4 Brain Cancer
 - 5.7.5 Others
- 5.8 Global Neoantigen Cancer Vaccine Market by Region
 - 5.8.1 Market Overview
 - 5.8.2 North America
 - 5.8.3 Europe
 - 5.8.4 Asia Pacific
 - 5.8.5 Latin America
 - 5.8.6 Middle East and Africa
- 6 North America Neoantigen Cancer Vaccine Market
 - 6.1 Market Share by Country
 - 6.2 United States of America
 - 6.3 Canada
- 7 Europe Neoantigen Cancer Vaccine Market
 - 7.1 Market Share by Country
 - 7.2 United Kingdom
 - 7.3 Germany
 - 7.4 France
 - 7.5 Italy
 - 7.6 Others
- 8 Asia Pacific Neoantigen Cancer Vaccine Market
 - 8.1 Market Share by Country
 - 8.2 China
 - 8.3 Japan
 - 8.4 India
 - 8.5 ASEAN
 - 8.6 Australia
 - 8.7 Others
- 9 Latin America Neoantigen Cancer Vaccine Market
 - 9.1 Market Share by Country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2□Brazil
- 9.3□Argentina
- 9.4□Mexico
- 9.5□Others
- 10□Middle East and Africa Neoantigen Cancer Vaccine Market
- 10.1□Market Share by Country
- 10.2□Saudi Arabia
- 10.3□United Arab Emirates
- 10.4□Nigeria
- 10.5□South Africa
- 10.6□Others
- 11□Patent Analysis
- 11.1□Analysis by Type of Patent
- 11.2□Analysis by Publication year
- 11.3□Analysis by Issuing Authority
- 11.4□Analysis by Patent Age
- 11.5□Analysis by CPC Analysis
- 11.6□Analysis by Patent Valuation
- 11.7□Analysis by Key Players
- 12□Grants Analysis
- 12.1□Analysis by year
- 12.2□Analysis by Amount Awarded
- 12.3□Analysis by Issuing Authority
- 12.4□Analysis by Grant Application
- 12.5□Analysis by Funding Institute
- 12.6□Analysis by NIH Departments
- 12.7□Analysis by Recipient Organization
- 13□Funding Analysis
- 13.1□Analysis by Funding Instances
- 13.2□Analysis by Type of Funding
- 13.3□Analysis by Funding Amount
- 13.4□Analysis by Leading Players
- 13.5□Analysis by Leading Investors
- 13.6□Analysis by Geography
- 14□Partnership and Collaborations Analysis
- 14.1□Analysis by Partnership Instances
- 14.2□Analysis by Type of Partnership
- 14.3□Analysis by Leading Players
- 14.4□Analysis by Geography
- 15□Regulatory Framework
- 15.1□Regulatory Overview
- 15.1.1□US FDA
- 15.1.2□EU EMA
- 15.1.3□INDIA CDSCO
- 15.1.4□JAPAN PMDA
- 15.1.5□Others
- 16□Supplier Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1 OSE Immunotherapeutics SA
 - 16.1.1 Financial Analysis
 - 16.1.2 Product Portfolio
 - 16.1.3 Demographic Reach and Achievements
 - 16.1.4 Mergers and Acquisition
 - 16.1.5 Certifications
- 16.2 Gritstone bio, Inc.
 - 16.2.1 Financial Analysis
 - 16.2.2 Product Portfolio
 - 16.2.3 Demographic Reach and Achievements
 - 16.2.4 Mergers and Acquisition
 - 16.2.5 Certifications
- 16.3 BioNTech SE
 - 16.3.1 Financial Analysis
 - 16.3.2 Product Portfolio
 - 16.3.3 Demographic Reach and Achievements
 - 16.3.4 Mergers and Acquisition
 - 16.3.5 Certifications
- 16.4 F. Hoffmann-La Roche Ltd.
 - 16.4.1 Financial Analysis
 - 16.4.2 Product Portfolio
 - 16.4.3 Demographic Reach and Achievements
 - 16.4.4 Mergers and Acquisition
 - 16.4.5 Certifications
- 16.5 Pfizer Inc.
 - 16.5.1 Financial Analysis
 - 16.5.2 Product Portfolio
 - 16.5.3 Demographic Reach and Achievements
 - 16.5.4 Mergers and Acquisition
 - 16.5.5 Certifications
- 16.6 Merck & Co. Inc.
 - 16.6.1 Financial Analysis
 - 16.6.2 Product Portfolio
 - 16.6.3 Demographic Reach and Achievements
 - 16.6.4 Mergers and Acquisition
 - 16.6.5 Certifications
- 16.7 Moderna Inc.
 - 16.7.1 Financial Analysis
 - 16.7.2 Product Portfolio
 - 16.7.3 Demographic Reach and Achievements
 - 16.7.4 Mergers and Acquisition
 - 16.7.5 Certifications
- 16.8 Avidia Technologies, Inc.
 - 16.8.1 Financial Analysis
 - 16.8.2 Product Portfolio
 - 16.8.3 Demographic Reach and Achievements
 - 16.8.4 Mergers and Acquisition

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.8.5□Certifications
- 16.9□Eli Lilly and Company
- 16.9.1□Financial Analysis
- 16.9.2□Product Portfolio
- 16.9.3□Demographic Reach and Achievements
- 16.9.4□Mergers and Acquisition
- 16.9.5□Certifications
- 16.10□Vaccibody AS
- 16.10.1□Financial Analysis
- 16.10.2□Product Portfolio
- 16.10.3□Demographic Reach and Achievements
- 16.10.4□Mergers and Acquisition
- 16.10.5□Certifications
- 16.11□Agenus Inc.
- 16.11.1□Financial Analysis
- 16.11.2□Product Portfolio
- 16.11.3□Demographic Reach and Achievements
- 16.11.4□Mergers and Acquisition
- 16.11.5□Certifications
- 16.12□Novogene Co., Ltd.
- 16.12.1□Financial Analysis
- 16.12.2□Product Portfolio
- 16.12.3□Demographic Reach and Achievements
- 16.12.4□Mergers and Acquisition
- 16.12.5□Certifications
- 16.13□ZIOPHARM Oncology Inc.
- 16.13.1□Financial Analysis
- 16.13.2□Product Portfolio
- 16.13.3□Demographic Reach and Achievements
- 16.13.4□Mergers and Acquisition
- 16.13.5□Certifications
- 16.14□ISA Pharmaceuticals B.V.
- 16.14.1□Financial Analysis
- 16.14.2□Product Portfolio
- 16.14.3□Demographic Reach and Achievements
- 16.14.4□Mergers and Acquisition
- 16.14.5□Certifications
- 16.15□BrightPath Biotherapeutics Co., Ltd.
- 16.15.1□Financial Analysis
- 16.15.2□Product Portfolio
- 16.15.3□Demographic Reach and Achievements
- 16.15.4□Mergers and Acquisition
- 16.15.5□Certifications
- 17□Global Neoantigen Cancer Vaccine Market - Distribution Model (Additional Insight)
- 17.1□Overview
- 17.2□Potential Distributors
- 17.3□Key Parameters for Distribution Partner Assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18☐Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19☐Company Competitiveness Analysis (Additional Insight)
 - 19.1☐Very Small Companies
 - 19.2☐Small Companies
 - 19.3☐Mid-Sized Companies
 - 19.4☐Large Companies
 - 19.5☐Very Large Companies
- 20☐Payment Methods (Additional Insight)
 - 20.1☐Government Funded
 - 20.2☐Private Insurance
 - 20.3☐Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031

Market Report | 2023-07-11 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com